Optinose Shares Cease Trading Following Acquisition

The publicly traded journey of Optinose has reached its conclusion. The specialty pharmaceutical company was acquired by Paratek Pharmaceuticals and is no longer listed on any stock exchange. As of May 21, 2025, the company's equity shares have been delisted.

Paratek Pharmaceuticals finalized the acquisition of Optinose before market open on May 21, 2025. This transaction followed shareholder approval that was secured on May 16, 2025. Under the terms of the deal, Optinose shareholders received compensation consisting of:

• A cash payment of $9.00 per share
• One contingent value right (CVR)
• Potential for up to $5.00 in additional payments if specific commercial milestones are achieved

This arrangement provided immediate liquidity to investors while allowing them to participate in the future success of the company's products.

Final Attempt to Maintain Listing

Prior to the acquisition, Optinose undertook a final effort to remain an independent, publicly-listed entity. The company executed a reverse stock split, a strategic maneuver designed to artificially increase its per-share trading price to comply with the Nasdaq's minimum bid price requirement.

Should investors sell immediately? Or is it worth buying Optinose?

This corporate action consolidated the number of outstanding shares from approximately 150.8 million down to about 10.1 million. Despite this measure, the company ultimately could not sustain its market position, paving the way for the acquisition by Paratek.

Delisting Marks the End of an Era

The completion of the acquisition triggered the immediate cessation of trading for Optinose stock. The Nasdaq made the delisting official by suspending the stock on May 22, 2025. This action marked the end of Optinose's tenure as a publicly traded company.

Key Details of the Delisting:
* Acquiring Entity: Paratek Pharmaceuticals
* Acquisition Closing Date: May 21, 2025
* Shareholder Approval Date: May 16, 2025
* Trading Suspension: May 21/22, 2025

New Chapter as a Subsidiary

Optinose now operates as a wholly-owned subsidiary within the Paratek Pharmaceuticals corporate structure. The company's core business—developing and commercializing specialty pharmaceuticals for ENT and allergy patients—continues, but it does so away from the public markets. For investors, this transition means that Optinose shares are now a part of financial history.